Sun Pharmaceuticals, India’s largest pharmaceutical company, has announced plans to launch Urteglutide, a GLP-1 receptor agonist, within the next four to five years. This experimental drug is being developed as a treatment for obesity and diabetes.
The move comes as Sun Pharmaceuticals watches the success of major players like Novo Nordisk and Eli Lilly, which have seen remarkable growth in the sales of their GLP-1 receptor agonist drugs, such as Wegovy and Zepbound. Inspired by their success, Sun is preparing to enter the booming GLP-1 market with its own version of these treatments.
Experts predict the global market for GLP-1 medications could soar to $150 billion by 2030. Wegovy and Zepbound are among the key players driving this growth, with both drugs making headlines for their effectiveness in managing weight and improving metabolic health.
Urteglutide, still in the experimental phase, is reported to have similar pharmacological effects to these leading treatments, including appetite suppression and prolonged feelings of fullness.
Sun Pharmaceuticals has also shared positive early results. The Phase 1 clinical trials for Urteglutide showed significant weight loss and improved metabolic function. The company plans to advance to mid-stage clinical trials later this year, bringing the drug one step closer to market approval.
